![Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study - eBioMedicine Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study - eBioMedicine](https://www.thelancet.com/cms/attachment/05922d60-976d-4395-81cb-244109ff7c7d/gr1_lrg.jpg)
Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study - eBioMedicine
![P = V I (1a) P = R I 2 (1b) P = V 2 / R (1c) where P = power (Watts) V = voltage (Volts)voltage I = current (Amperes) R = resistance (Ohms) - ppt download P = V I (1a) P = R I 2 (1b) P = V 2 / R (1c) where P = power (Watts) V = voltage (Volts)voltage I = current (Amperes) R = resistance (Ohms) - ppt download](https://slideplayer.com/10135057/33/images/slide_1.jpg)